| ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas KC Wiegand, SP Shah, OM Al-Agha, Y Zhao, K Tse, T Zeng, J Senz, ... New England Journal of Medicine 363 (16), 1532-1543, 2010 | 1895 | 2010 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1652 | 2017 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1586 | 2017 |
| Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary SP Shah, M Köbel, J Senz, RD Morin, BA Clarke, KC Wiegand, G Leung, ... New England Journal of Medicine 360 (26), 2719-2729, 2009 | 854 | 2009 |
| Oral contraceptives and the risk of hereditary ovarian cancer SA Narod, H Risch, R Moslehi, A Dørum, S Neuhausen, H Olsson, ... New England Journal of Medicine 339 (7), 424-428, 1998 | 852 | 1998 |
| Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre … SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The lancet oncology 19 (3), 295-309, 2018 | 557 | 2018 |
| Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study UA Matulonis, R Shapira-Frommer, AD Santin, AS Lisyanskaya, S Pignata, ... Annals of Oncology 30 (7), 1080-1087, 2019 | 549 | 2019 |
| 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG … A Du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, ... Annals of oncology 16, viii7-viii12, 2005 | 546 | 2005 |
| Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers SA Narod, MP Dubé, J Klijn, J Lubinski, HT Lynch, P Ghadirian, ... Journal of the National Cancer Institute 94 (23), 1773-1779, 2002 | 477 | 2002 |
| Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a … SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The lancet oncology 20 (9), 1273-1285, 2019 | 385 | 2019 |
| Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group AM Oza, L Elit, MS Tsao, S Kamel-Reid, J Biagi, DM Provencher, ... Journal of Clinical Oncology 29 (24), 3278, 2011 | 385 | 2011 |
| Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial BJ Monk, A Poveda, I Vergote, F Raspagliesi, K Fujiwara, DS Bae, ... The lancet oncology 15 (8), 799-808, 2014 | 347 | 2014 |
| Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I NC te Grootenhuis, AGJ Van Der Zee, HC Van Doorn, J van der Velden, ... Gynecologic oncology 140 (1), 8-14, 2016 | 286 | 2016 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double … A Poveda, A Floquet, JA Ledermann, R Asher, RT Penson, AM Oza, ... The Lancet Oncology 22 (5), 620-631, 2021 | 280 | 2021 |
| Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC) M Zietarska, CM Maugard, A Filali‐Mouhim, M Alam‐Fahmy, PN Tonin, ... Molecular Carcinogenesis: Published in cooperation with the University of …, 2007 | 259 | 2007 |
| Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes YK Wang, A Bashashati, MS Anglesio, DR Cochrane, DS Grewal, G Ha, ... Nature genetics 49 (6), 856-865, 2017 | 251 | 2017 |
| Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated … AM Oza, AV Tinker, A Oaknin, R Shapira-Frommer, IA McNeish, ... Gynecologic oncology 147 (2), 267-275, 2017 | 250 | 2017 |
| Characterization of four novel epithelial ovarian cancer cell lines DM Provencher, H Lounis, L Champoux, M Tetrault, EN Manderson, ... In vitro cellular & developmental biology. Animal, 357-361, 2000 | 239 | 2000 |
| Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer BY Karlan, AM Oza, GE Richardson, DM Provencher, VL Hansen, M Buck, ... Journal of clinical oncology 30 (4), 362-371, 2012 | 233 | 2012 |
| Clinical trials in recurrent ovarian cancer M Friedlander, E Trimble, A Tinker, D Alberts, E Avall-Lundqvist, M Brady, ... International Journal of Gynecologic Cancer 21 (4), 2011 | 229 | 2011 |
